SCHEMBL3751790

SCHEMBL3751790

[CH2]Cc1ccc(F)c(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
FAAH O00519 1/20 0.41
PARP1 P09874 3/20 0.38
EGFR P00533 1/20 0.36
VCP P55072 1/20 0.34
MAOB P27338 2/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
MAOA P21397 1/20 0.33
GRIN1 Q05586 1/20 0.32
GRIN2B Q13224 1/20 0.32
IDO1 P14902 2/20 0.32
TDO2 P48775 1/20 0.32
DYRK1A Q13627 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8079708 0.82 KDM1A (0.37) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL11244115 0.79 KDM4E (0.49) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL333551 0.79 CYP1A2 (0.53) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL29418197 0.79 CYP1A2 (0.53) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL126440 0.78 HTT (0.45) MAOBALDH1A1MAOARAB9A
SCHEMBL838854 0.78 FAAH (0.37) KDM4EFAAH
SCHEMBL3400966 0.77 KDM4E (0.47) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL51845 0.77 KDM4E (0.47) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL604198 0.77 CYP1A2 (0.51) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL15352304 0.77 KDM4E (0.47) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017201683-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-30 WO disclosed
CN-102791803-B Composition for ultraviolet absorbing member and ultraviolet absorbing member using same SUMITOMO SEIKA CHEMICALS 2015-07-01 CN disclosed
US-8540904-B2 Composition for ultraviolet absorbent substance and ultraviolet absorbent substance comprising same SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2013-09-24 US disclosed
US-8426631-B2 Fungicidal compounds, method for the production thereof, and use thereof to combat damaging fungi, and agents comprising the same BASF SE (DE) 2013-04-23 US disclosed
US-20120313058-A1 COMPOSITION FOR ULTRAVIOLET ABSORBENT SUBSTANCE AND ULTRAVIOLET ABSORBENT SUBSTANCE COMPRISING SAME SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2012-12-13 US disclosed
CN-102791803-A Composition for ultraviolet absorbing member and ultraviolet absorbing member using same SUMITOMO SEIKA CHEMICALS 2012-11-21 CN disclosed
US-20100304966-A1 Fungicidal Compounds, Method For the Production Thereof, And Use Thereof To Combat Damaging Fungi, And Agents Comprising The Same BASF SE (DE) 2010-12-02 US disclosed
CN-1968945-A Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase WYETH CORP (US) 2007-05-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100304966-A1 Fungicidal Compounds, Method For the Production Thereof, And Use Thereof To Combat Damaging Fungi, And Agents Comprising The Same CYP51A1, ERG28, CAT KDM4E 856/4885CYP1A2 22/4885CYP2D6 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.